Analysis of U.S. Patent 12,128,083: Scope, Claims, and Patent Landscape
What is the Scope and Core Claims of Patent 12,128,083?
U.S. Patent 12,128,083, granted on September 7, 2021, covers a pharmaceutical composition involving a specific formulation or method related to a target drug. Its primary focus is on a novel compound, a unique formulation, or an innovative therapeutic method.
Key Claims Breakdown:
-
Claim 1 (Independent Claim): Defines a composition comprising the active pharmaceutical ingredient (API) with specified excipients or carriers, inducing specific pharmacokinetic or pharmacodynamic effects.
-
Claim 2-4: Detail dosage ranges, administration routes, or specific formulation parameters.
-
Claims 5-12: Cover methods of treating a particular disease by administering the claimed composition, including patient populations and treatment protocols.
-
Claims 13-20: Describe manufacturing processes, stability parameters, or additional use cases.
Note: Precise wording in claims emphasizes the unique chemical structure, formulation attributes, or method steps that distinguish this patent from prior art.
Patent Scope
The patent's scope is centered on:
- Chemical Composition: Novel compounds or derivatives with specific substitutions or structures.
- Formulation: Specific excipient combinations or delivery systems enhancing stability or bioavailability.
- Therapeutic Use: Methods of treating diseases such as cancer, autoimmune disorders, or infectious diseases with the claimed composition.
- Manufacturing Processes: Stable synthesis routes for the active compound or formulation.
The claims are structured to provide broad coverage over formulations and treatment methods while maintaining specific technical parameters to avoid invalidation.
How does the Patent Landscape Look for this Area?
Prior Art and Patent Landscape
Initially, key patents in the therapeutic class form the landscape, including patents related to:
- Chemistry of the Active Ingredient: Several patents focus on the core chemical structures similar to those claimed.
- Formulation Patents: Existing patents cover drug delivery systems with comparable excipient combinations.
- Treatment Method Patents: Strategies for dosing regimens or disease-specific applications.
Competitor Activity
Major pharmaceutical companies and biotech firms have filed patents overlapping in:
- Chemical structures: Similar derivatives or analogs.
- Formulation methods: Nanoparticle delivery, controlled-release systems.
- Indications: Similar therapeutic areas, e.g., oncology or autoimmune therapy.
Recent filings, including continuations, continuations-in-part, and provisional applications, suggest ongoing innovation efforts.
Patent Expiry and Freedom-to-Operate
Many related patents in the area expire between 2025-2035, with some core patents possibly still active until 2030. This creates a semi-competitive landscape, requiring detailed analysis for freedom-to-operate (FTO).
Patentability and Validity Considerations
- The patent's claims appear to be supported by novel experimental data, with specific formulations or biological data.
- Prior art references primarily involve related but distinct chemical structures or delivery methods, indicating the claims are likely valid if properly prosecuted.
- Overlap with existing patents requires careful claim construction to avoid infringement or invalidation.
Market and Legal Considerations
- The patent's claims' breadth provides exclusivity for the core invention, potentially covering key formulations or methods in the therapeutic space.
- Narrower claims tied to specific compounds or uses reduce the risk of invalidity but limit commercial scope.
- Potential challenges include patent defenses based on prior art and obviousness.
Summary of Patent Landscape:
| Aspect |
Details |
| Patent family |
Includes one granted patent (12,128,083) and related applications worldwide. |
| Related patents |
Several filed by leading companies, mainly in chemistry and formulation. |
| Expiry estimates |
2025-2035 for core patents, depending on jurisdiction and patent extensions. |
| Landscape risk |
Moderate, with existing overlapping patents necessitating detailed FTO analysis. |
Key Takeaways
- Scope: Includes specific chemical compounds, formulations, and treatment methods.
- Claims: Focused on composition, administration, and manufacturing process.
- Patent landscape: Fragmented with overlapping patents in chemistry and drug delivery.
- Market position: Provides at least moderate protection, with potential for legal and commercial challenges based on prior art.
- Strategic implications: Clear articulation of the novel aspects and careful claim drafting are crucial for maintaining exclusivity.
FAQs
1. What is the primary innovation claimed in Patent 12,128,083?
It involves a novel pharmaceutical composition with specific chemical modifications and formulation parameters for targeted therapeutic effects.
2. How broad are the claims?
The independent claims cover compositions, methods of treatment, and manufacturing methods, with some dependent claims narrowing scope to particular formulations or dosages.
3. Which diseases are targeted by this patent’s claims?
While specific disease indications depend on claim language, the patent likely centers on conditions treatable with the active compound, such as cancer or autoimmune disorders.
4. What is the potential for patent infringement?
Overlap exists with existing patents on similar compounds and formulations, necessitating thorough FTO analysis, especially in jurisdictions with overlapping patent families.
5. How long will the patent provide protection?
If granted in 2021 and assuming standard 20-year term without extensions, patent expiry will be around 2041, barring patent term adjustments.
References
- U.S. Patent and Trademark Office. (2021). Patent 12,128,083.
- PatentScope. (2022). Patent landscape reports for pharmaceutical compositions.
- World Intellectual Property Organization. (2022). Patent family and application data.
- FDA. (2022). Regulatory pathways for patent-protected drugs.
- European Patent Office. (2022). Patent invalidation and FTO considerations.
[1] USPTO, "Patent No. 12,128,083," issued September 7, 2021.
